Kodiak Sciences Inc. (KOD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1200 Page Mill Road
Palo Alto, CA 94304
United States of America (the)
Phone
650 281 0850
Website
Sector
Healthcare
Industry
Biotechnology
Employees
109
First IPO Date
October 04, 2018
| Name | Title | Pay | Year Born |
| Victor Perlroth | Co-Founder, Chairman, Chief Executive Officer & President | 1.58M | 1974 |
| Hong Liang | Senior Vice President of Development | 300,709 | 1972 |
| John A. Borgeson | Executive Vice President, Chief Financial Officer & Secretary | 937,157 | 1963 |
| Almas Qudrat | Chief Quality Officer | 0 | N/A |
| J. Pablo Velazquez-Martin | Chief Medical Officer | 0 | N/A |
| Laurent Ducay | Senior Vice President of Biologics Development & Manufacturing | 0 | N/A |
| Laurent Ducry | Senior Vice President of Biologics Development & Manufacturing | 0 | N/A |
| Wayne To | Chief Technology Officer | 0 | N/A |
| Stephen Raillard | Senior Vice President of Chemical Development & Manufacturing | 0 | N/A |
| Dolly S. Chang | Chief Scientific Officer | 0 | N/A |
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.